Market research
APS.TO Aptose Biosciences Inc
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 2.358
- Dividend yield
- Not available
- Beta
- 0.34
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA03835T2002
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 2.358
- Dividend yield
- Not available
- Beta
- 0.34
About
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the APS.TO discussion.
5 years, 5 months ago
Aptose Biosciences Inc is currently in a long term downtrend where the price is trading 33.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Aptose Biosciences Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 90.9% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 66.3% to $-10M since the same quarter in the previous year.
Based on the above factors, Aptose Biosciences Inc gets an overall score of 1/5.